(Albany, New York) – 2nd Sep 2026 – The market dynamics for Complement 3 Glomerulopathy (C3G) are witnessing significant growth driven by increasing understanding of complement dysregulation, advancements in diagnostic capabilities, growing use of genetic testing and complement assays, and the expansion of targeted complement therapies. Additionally, the approval and expanding adoption of FABHALTA (iptacopan) and EMPAVELI/ASPAVELI (pegcetacoplan), along with the development of promising pipeline candidates such as KP104, Zaltenibart (OMS906), Ruxoprubart (NM8074), and ARO-C3, are expected to further propel the Complement 3 Glomerulopathy market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Complement 3 Glomerulopathy Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Complement 3 Glomerulopathy, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Complement 3 Glomerulopathy Market
The market size for Complement 3 Glomerulopathy in the leading markets is expected to grow significantly by 2036.
The 7MM Complement 3 Glomerulopathy market is projected to reach approximately USD 1 billion by 2036, reflecting a 28% CAGR during 2026–2036.
According to DelveInsight’s estimates, the Complement 3 Glomerulopathy diagnosed prevalent population in the 7MM was around 6,000 in 2025 and is expected to rise through 2036.
The United States accounted for approximately 3,500 diagnosed prevalent cases of Complement 3 Glomerulopathy in 2025.
In 2025, Complement 3 Glomerulopathy predominantly affected adults in the United States, accounting for approximately 90% of cases, while the pediatric population represented the remaining 10%.
In 2025, the United States accounted for approximately 70% of the 7MM Complement 3 Glomerulopathy treatment market, making it the largest market compared with EU4 and the UK and Japan.
FABHALTA (iptacopan) became the first FDA-approved therapy for C3G, targeting the alternative complement pathway through Factor B inhibition.
EMPAVELI/ASPAVELI (pegcetacoplan) provides a targeted approach by inhibiting C3 directly and proximally within the complement cascade and has demonstrated notable clinical efficacy in C3G.
Leading Complement 3 Glomerulopathy companies, including Novartis, Apellis Pharmaceuticals, Sobi, Kira Pharmaceuticals, Novo Nordisk/Omeros Corporation, Arrowhead Pharmaceuticals, and others, are actively developing innovative therapies expected to transform the C3G treatment landscape over the coming years.
Promising Complement 3 Glomerulopathy therapies in clinical development include KP104, Zaltenibart (OMS906), Ruxoprubart (NM8074), ARO-C3, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Key Factors Driving the Complement 3 Glomerulopathy MarketAdvancements in Complement Biology and Targeted Therapies
A deeper understanding of complement dysregulation has improved the identification of therapeutic targets within the alternative complement pathway. The development of therapies targeting different components of the complement cascade is expanding treatment options for patients with C3G.
Improved Diagnostic Capabilities
The widespread use of complement assays, genetic testing, and renal biopsy interpretation is enabling earlier and more accurate diagnosis of C3G. Increased multidisciplinary collaboration and advances in specialized diagnostics are also contributing to better identification of patients with this rare kidney disease.
Increasing Recognition of C3G Disease Burden
Increased reporting and retrospective chart reviews in nephrology centers suggest that C3G may be more common than previously believed, particularly in regions with improved access to specialized diagnostic services. The progressive nature of C3G and its high risk of kidney disease progression further highlight the need for effective treatment options.
Expansion of the Complement 3 Glomerulopathy Pipeline
The C3G pipeline is expanding with therapies targeting novel mechanisms, including dual complement inhibition, MASP-3 inhibition, and RNA interference targeting complement C3. These approaches are expected to provide additional treatment options and contribute to market growth during the forecast period.
Complement 3 Glomerulopathy Competitive Landscape
The Complement 3 Glomerulopathy treatment landscape has evolved significantly with the introduction of targeted complement therapies. Historically, management has relied heavily on supportive and off-label treatments, including corticosteroids, immunosuppressive drugs, ACE inhibitors, ARBs, calcineurin inhibitors, and monoclonal antibodies such as eculizumab and rituximab.
The approval of FABHALTA (iptacopan) marked a significant advancement in C3G treatment. Iptacopan is an oral Factor B inhibitor that targets the alternative complement pathway. By binding to Factor B, it inhibits alternative pathway activation and reduces complement-mediated injury within the glomeruli.
EMPAVELI/ASPAVELI (pegcetacoplan) represents another important advancement by targeting C3 directly and proximally within the complement cascade. The therapy has been approved for C3G and primary IC-MPGN and provides a broader upstream approach to complement inhibition.
The emerging pipeline includes therapies with differentiated mechanisms of action. KP104 is a dual-targeting complement inhibitor designed to simultaneously inhibit C5 and Factor H. Zaltenibart (OMS906) is an investigational MASP-3 inhibitor targeting the alternative complement pathway, while ARO-C3 is an RNA interference therapeutic designed to target complement C3. Ruxoprubart (NM8074) is an engineered human immunoglobulin designed to selectively block the alternative pathway by binding Bb.
These emerging therapies are expected to further reshape the Complement 3 Glomerulopathy treatment landscape over the forecast period.
Discover more about therapies set to grab major Complement 3 Glomerulopathy market share @ Complement 3 Glomerulopathy Treatment Landscape
Recent Developments in the Complement 3 Glomerulopathy Market
In January 2026, Sobi announced that the European Commission approved ASPAVELI (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3G or primary IC-MPGN in combination with a renin-angiotensin system inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
In June 2025, Apellis Pharmaceuticals presented new data from the open-label period of the Phase III VALIANT study, investigating pegcetacoplan for C3G and primary IC-MPGN, during a late-breaking session at the ERA Congress.
In July 2025, the US FDA approved pegcetacoplan as the first treatment for C3G or primary IC-MPGN in patients 12 years of age and older.
In March 2025, iptacopan (FABHALTA) received US FDA approval for the treatment of adults with C3G.
In April 2025, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for iptacopan for the treatment of adults with C3G.
What is Complement 3 Glomerulopathy?
Complement 3 Glomerulopathy (C3G) is a group of rare kidney diseases caused by dysregulation of the alternative complement pathway. The condition is characterized by predominant deposition of complement component C3 within the glomeruli, with minimal or absent immunoglobulin, C1q, and C4.
C3G includes two major forms: Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN). These forms differ according to their patterns of damage and inflammation within the glomeruli, with features of DDD generally appearing earlier, often during adolescence.
Patients with C3G may present with proteinuria, hematuria, reduced urine output, low blood protein levels, and edema. Diagnosis typically requires a kidney biopsy, including light microscopy, immunofluorescence, and electron microscopy. Additional assessments may include urine and blood tests and measurement of glomerular filtration rate.
C3G has a challenging long-term outlook due to its progressive course and high risk of recurrence. Approximately 30–50% of patients develop end-stage kidney disease within 10 years of diagnosis, highlighting the significant unmet need for effective disease-modifying therapies.
Complement 3 Glomerulopathy Epidemiology Segmentation
The Complement 3 Glomerulopathy epidemiology section provides insights into the historical and current C3G patient pool and forecasted trends across the seven major markets. The Complement 3 Glomerulopathy market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy
Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy
Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy
Total Treated Cases of Complement 3 Glomerulopathy
Scope of the Complement 3 Glomerulopathy Market Report
Therapeutic Assessment: Current marketed and emerging therapies for Complement 3 Glomerulopathy
Complement 3 Glomerulopathy Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook
Key Companies: Novartis, Apellis Pharmaceuticals, Sobi, Kira Pharmaceuticals, Novo Nordisk/Omeros Corporation, Arrowhead Pharmaceuticals, and others
Key Therapies: FABHALTA (iptacopan), EMPAVELI/ASPAVELI (pegcetacoplan), KP104, Zaltenibart (OMS906), Ruxoprubart (NM8074), ARO-C3, and others
Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, KOL Views, and Market Assessment
Unmet Needs, KOL’s Views, Analyst’s Views, Complement 3 Glomerulopathy Market Access and Reimbursement
To know more about Complement 3 Glomerulopathy companies working in the treatment market, visit @ Complement 3 Glomerulopathy Clinical Trials and Therapeutic Assessment
Table of Contents
Complement 3 Glomerulopathy Market Report Introduction
Executive Summary for Complement 3 Glomerulopathy
Key Events of Complement 3 Glomerulopathy
SWOT Analysis of Complement 3 Glomerulopathy
Complement 3 Glomerulopathy Patient Share (%) Overview at a Glance
Complement 3 Glomerulopathy Market Overview at a Glance
Complement 3 Glomerulopathy Background and Overview
Complement 3 Glomerulopathy Epidemiology and Patient Population
Country-Specific Patient Population of Complement 3 Glomerulopathy
Complement 3 Glomerulopathy Current Treatment and Medical Practices
Complement 3 Glomerulopathy Unmet Needs
Complement 3 Glomerulopathy Emerging Therapies
Complement 3 Glomerulopathy Market Outlook
Country-Wise Complement 3 Glomerulopathy Market Analysis (2022–2036)
Complement 3 Glomerulopathy Market Access and Reimbursement of Therapies
Complement 3 Glomerulopathy Market Drivers
Complement 3 Glomerulopathy Market Barriers
Complement 3 Glomerulopathy Appendix
Complement 3 Glomerulopathy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
